160 related articles for article (PubMed ID: 33870432)
1. Pegylated Interferon-ɑ (IFN-ɑ) Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN-γ in Chronic Hepatitis B.
Yuan W; Huang D; Wu D; Chen Y; Ma K; Han M; Luo X; Yan W; Ning Q
J Infect Dis; 2021 Dec; 224(11):1878-1889. PubMed ID: 33870432
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
4. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients.
Pang X; Zhang L; Liu N; Liu B; Chen Z; Li H; Chen M; Peng M; Ren H; Hu P
Clin Exp Immunol; 2020 Oct; 202(1):80-92. PubMed ID: 32638357
[TBL] [Abstract][Full Text] [Related]
5. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
7. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.
Micco L; Peppa D; Loggi E; Schurich A; Jefferson L; Cursaro C; Panno AM; Bernardi M; Brander C; Bihl F; Andreone P; Maini MK
J Hepatol; 2013 Feb; 58(2):225-33. PubMed ID: 23046671
[TBL] [Abstract][Full Text] [Related]
8. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8
Xun Z; Lin J; Yu Q; Liu C; Huang J; Shang H; Guo J; Ye Y; Wu W; Zeng Y; Wu S; Xu S; Chen T; Chen J; Ou Q
Cell Mol Immunol; 2021 Feb; 18(2):461-471. PubMed ID: 33432062
[TBL] [Abstract][Full Text] [Related]
9. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
10. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
11. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.
Boni C; Lampertico P; Talamona L; Giuberti T; Invernizzi F; Barili V; Fisicaro P; Rossi M; Cavallo MC; Vecchi A; Pedrazzi G; Alfieri A; Colombo M; Missale G; Ferrari C
Hepatology; 2015 Dec; 62(6):1697-709. PubMed ID: 26361374
[TBL] [Abstract][Full Text] [Related]
13. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
14. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.
Cao W; Li M; Zhang L; Lu Y; Wu S; Shen G; Chang M; Liu R; Gao Y; Hao H; Hu L; Yi W; Pan CQ; Xie Y
Biomed Res Int; 2021; 2021():2178143. PubMed ID: 33575322
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B.
Chen J; Wang Y; Wu XJ; Li J; Hou FQ; Wang GQ
World J Gastroenterol; 2010 Dec; 16(48):6145-50. PubMed ID: 21182232
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
[TBL] [Abstract][Full Text] [Related]
17. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
[TBL] [Abstract][Full Text] [Related]
18. The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy.
Lou S; Wang J; Chen J; Xie H; Chen H; Zhou B; Zhang B; Hou J; Jiang DK
J Infect Dis; 2023 Sep; 228(6):694-703. PubMed ID: 36932045
[TBL] [Abstract][Full Text] [Related]
19. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
20. RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B.
Wu S; Lin J; Fu Y; Ou Q
Antivir Ther; 2018; 23(7):575-583. PubMed ID: 29790851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
